Delivery Order SPE2DR25D9239-SPE2DR26FFBW1
- Not listed
- The Defense Logistics Agency (DLA) awarded a $39,900 delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for Fasenra 30 mg/mL syringes. The award, issued on December 17, 2025, with a completion date of December 18, 2025, represents a firm fixed-price delivery order with no set-aside designation. This contract leverages DMS Pharmaceutical Group's position as a regional prime vendor under the DLA's Pharmaceutical...
- The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $24,435 to DMS Pharmaceutical Group Inc. for Fasenra 30 mg/ml syringes. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, was selected without a set-aside designation, demonstrating its competitive capability in unrestricted federal procurement. The delivery order is scheduled for completion by November 3, 2025, and represents one of numerous...
- The Defense Logistics Agency awarded a $24,937.50 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Fasenra 30 mg/mL syringes. The delivery order, issued on November 24, 2025, with an ultimate completion date of November 25, 2025, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. This award falls under...
- The Defense Logistics Agency (DLA) awarded a $14,962.50 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for Fasenra 30 mg/ml syringes. The award, issued on December 2, 2025, with an ultimate completion date of December 3, 2025, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. DMS Pharmaceutical Group was selected as...
- The Defense Logistics Agency awarded a $9,975 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for Fasenra Pen 30 mg/ml on January 7, 2026. This delivery order, which carries no set-aside designation, is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G...
- The Defense Logistics Agency awarded a $4,987.50 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for 30 mg/mL Fasenra pen medication. The delivery order, issued on January 12, 2026 with an ultimate completion date of January 13, 2026, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. This award was made without...
- The Defense Logistics Agency awarded a $4,987.50 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for Fasenra 30 mg/ml syringes. The award, issued on January 6, 2026, with an ultimate completion date of January 7, 2026, was made without a set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. Performance will take place in...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,493.75 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Fasenra Pen 30 mg/mL. The contract is a firm fixed-price delivery order with an ultimate completion date of January 7, 2026, and was issued without a set-aside designation. DMS Pharmaceutical Group is performing work at its headquarters location in Park Ridge, Illinois. This...
- The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract worth $7,330.50 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the provision of Fasenra 30 mg/ml syringes, and is part of a larger indefinite delivery contract (IDC) with DMS Pharmaceutical Group valued at up to $499,999,999 that runs through December 31, 2025. This IDC, under the SPE2DB program, allows the DLA to issue...
- The Defense Logistics Agency awarded a delivery order valued at $2,493.75 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Fasenra Pen 30 mg/ml. The delivery order, issued on January 9, 2026, with an ultimate completion date of January 12, 2026, operates under a firm fixed-price contract structure with no set-aside designation. DMS Pharmaceutical Group is performing work at its headquarters location in...
- SPE2DR25D9239Indefinite Delivery Contract
- SPE2DR25D9239-SPE2DR26FFBW1Delivery Order
The Defense Logistics Agency awarded a $14,962.50 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Fasenra 30 mg/ml syringes. This delivery order, issued on January 12, 2026, with an ultimate completion date of January 13, 2026, carries no set-aside designation and represents a competitive procurement under DMS Pharmaceutical Group's existing pharmaceutical supply contract. The award was funded by the Defense Logistics Agency's Medical Supply Chain division to support Department of Defense healthcare operations. This delivery order falls under DMS Pharmaceutical Group's Indefinite Delivery Contract (IDC) with the Defense Logistics Agency designated as contract SPE2DR, awarded on November 13, 2025, as part of the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative. The broader PPV-G GEN V acquisition strategy, valued at $30.3 billion, establishes DMS Pharmaceutical Group as one of multiple regional prime vendor contractors authorized to supply a comprehensive range of pharmaceutical products, biologics, and medical consumables to military healthcare facilities worldwide. The parent IDC carries a $499,999,999 ceiling value and extends through December 31, 2036, positioning DMS Pharmaceutical Group as a critical supplier within the Department of Defense's pharmaceutical supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $15.0k | 1/11/26 |